» Authors » Brian A Belt

Brian A Belt

Explore the profile of Brian A Belt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 3014
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ye J, Qin S, Hughson A, Hannon G, Vrooman T, Lesch M, et al.
Cancers (Basel) . 2025 Jan; 17(2). PMID: 39857986
: Pancreatic ductal adenocarcinoma (PDAC), expecting to be the second leading cause of cancer deaths by 2030, resists immune checkpoint therapies due to its immunosuppressive tumor microenvironment (TME). Leukemia inhibitory...
2.
Burchard P, Ruffolo L, Ullman N, Dale B, Dave Y, Hilty B, et al.
Hepatol Commun . 2024 Aug; 8(8). PMID: 39101793
Background: Cholangiocarcinoma (CCA) features highly desmoplastic stroma that promotes structural and functional resistance to therapy. Lysyl oxidases (LOX, LOXL1-4) catalyze collagen cross-linking, thereby increasing stromal rigidity and facilitating therapeutic resistance....
3.
Peng X, Kharitonova E, Xu Y, Kearney J, Luan C, Chan P, et al.
bioRxiv . 2024 May; PMID: 38798565
Significance: We introduce a replicable and robust classifier, DeCAF, that delineates the significance of the role of permissive and restraining CAF subtypes in cancer patients. DeCAF is clinically tractable, prognostic...
4.
Alexander W, Wang W, Hill M, ODell M, Ruffolo L, Guo B, et al.
Dis Model Mech . 2024 Feb; 17(6. PMID: 38415925
Cholangiocarcinoma (CCA) is a deadly and heterogeneous type of cancer characterized by a spectrum of epidemiologic associations as well as genetic and epigenetic alterations. We seek to understand how these...
5.
Ye J, Gavras N, Keeley D, Hughson A, Hannon G, Vrooman T, et al.
J Immunother Cancer . 2023 May; 11(5). PMID: 37142292
Background: Stereotactic body radiotherapy (SBRT) induces immunogenic cell death, leading to subsequent antitumor immune response that is in part counterbalanced by activation of immune evasive processes, for example, upregulation of...
6.
Ye J, Mills B, Qin S, Garrett-Larsen J, Murphy J, Uccello T, et al.
J Immunother Cancer . 2022 Jul; 10(7). PMID: 35851308
Background: Stereotactic body radiotherapy (SBRT) has been increasingly used as adjuvant therapy in pancreatic ductal adenocarcinoma (PDAC), and induces immunogenic cell death, which leads to the release of tumor antigen...
7.
Ruffolo L, Zambrano D, Dale B, Nimmagadda S, Hack M, Gaba H, et al.
J Surg Res . 2022 Jul; 279:228-239. PMID: 35792450
Introduction: Pernicious health disparities have been reported in patients with hepatocellular carcinoma (HCC). Few tools exist to screen patients in order to facilitate educational and outreach initiatives. We hypothesize that...
8.
Mills B, Qiu H, Drage M, Chen C, Mathew J, Garrett-Larsen J, et al.
Clin Cancer Res . 2021 Dec; 28(1):150-162. PMID: 34862242
Purpose: Stereotactic body radiotherapy (SBRT) is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC), which can effectively prime cytotoxic T cells by inducing immunogenic tumor cell death in preclinical...
9.
Ruffolo L, Jackson K, Kuhlers P, Dale B, Figueroa Guilliani N, Ullman N, et al.
Gut . 2021 Aug; 71(7):1386-1398. PMID: 34413131
Objective: Intrahepatic cholangiocarcinoma (iCCA) is rising in incidence, and at present, there are limited effective systemic therapies. iCCA tumours are infiltrated by stromal cells, with high prevalence of suppressive myeloid...
10.
Han B, Murphy J, Qin S, Ye J, Uccello T, Garrett-Larsen J, et al.
Immunol Invest . 2020 Jun; 49(7):808-823. PMID: 32498585
Introduction: The tumor-draining lymph node (TDLN) plays a role in tumor immunity. Intratumorally administered microspheres (MS) that encapsulate immunomodulatory agents have emerged as a treatment strategy capable of causing profound...